Article Text

PDF
Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis
  1. P Tynjälä1,2,
  2. P Lahdenne1,
  3. P Vähäsalo3,
  4. H Kautiainen2,
  5. V Honkanen1,2
  1. 1Department of Paediatric Rheumatology, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
  2. 2Department of Children and Adolescents, Rheumatism Foundation Hospital, Heinola, Finland
  3. 3Department of Paediatrics, Oulu University Hospital, Oulu, Finland
  1. Correspondence to:
    Dr Pirjo Tynjälä
    Hospital for Children and Adolescents, Helsinki University Central Hospital, Research Unit, Lastenlinnantie 11 C 29, PL 280, 00029 HUS, Finland; pirjo.tynjala{at}hus.fi

Abstract

Objectives: To evaluate the impact of anti-tumour necrosis factor (TNF) treatment on growth and to identify the predictors for the change in growth in severe juvenile idiopathic arthritis (JIA).

Methods: Data from 71 JIA patients (43 on etanercept, 28 on infliximab) were reviewed two years before and two years on the anti-TNF treatment. The patients had polyarticular disease course (48 polyarthritis, 19 extended oligoarthritis, two systemic arthritis, and two enthesitis related arthritis). At the initiation of the anti-TNF treatment, their mean age was 9.6 years and the mean duration of JIA, 5.7 years.

Results: In the patients with delayed growth before anti-TNF treatment (n = 53), the growth velocity, measured as the change in height standard deviation score, accelerated +0.45 (95% confidence interval, 0.33 to 0.56) (p<0.001) during the anti-TNF treatment. In the patients with normal or accelerated growth before anti-TNF treatment (n = 18), the change in growth velocity was +0.05 (0.07 to 0.16) (p = 0.39). At two years on anti-TNF treatment, the growth velocity between these two groups was similar. No difference was found between the patients treated with etanercept or infliximab. A decelerating growth rate before the anti-TNF treatment was the strongest predictor for the observed increase in the growth velocity. The change in the inflammatory activity remained a significant predictor of the growth velocity even after the decrease in glucocorticoid dose was taken into account.

Conclusions: In the treatment of polyarticular JIA, the anti-TNF treatment not only suppresses inflammation but also restores growth velocity.

  • HSDS, height standard deviation score
  • ILAR, International League of Associations for Rheumatology
  • JIA, juvenile idiopathic arthritis
  • TNF, tumour necrosis factor
  • juvenile idiopathic arthritis
  • anti-TNF treatment
  • growth

Statistics from Altmetric.com

Footnotes

  • Published Online First 31 January 2006

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.